Patents by Inventor Robin Barbour

Robin Barbour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220372118
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: November 24, 2022
    Applicant: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu
  • Patent number: 11492393
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: November 8, 2022
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 11440953
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: September 13, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Patent number: 11434283
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Patent number: 11434285
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Patent number: 11434284
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Publication number: 20220275067
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 1, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Philip James DOLAN, III, Tarlochan S. NIJJAR, Svetlana ALEXANDER, Robin BARBOUR, Stephen Jed TAM
  • Publication number: 20220242940
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 4, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220153821
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 19, 2022
    Inventors: Tarlochan S. NIJJAR, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
  • Publication number: 20220089762
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: March 24, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220089702
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 24, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE
  • Patent number: 11267877
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 8, 2022
    Inventors: Joshua Reginald Salmans, Svetlana Alexander, Robin Barbour, Jeffrey N. Higaki, Tarlochan S. Nijjar
  • Publication number: 20220049009
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 17, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220041699
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220041700
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Publication number: 20220041701
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Patent number: 11237176
    Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 1, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventor: Robin Barbour
  • Publication number: 20210261652
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 26, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
  • Publication number: 20210165000
    Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.
    Type: Application
    Filed: October 30, 2020
    Publication date: June 3, 2021
    Inventors: Robin Barbour, Lynn R. Zieske, Sarah Hamren
  • Publication number: 20210130449
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz